



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Application No.:

K. Schoenafinger, et al

10/617,498

Filed:

July 11, 2003

Title:

Heterocyclically Substituted

Benzoylureas, Process for Their Preparation and Their use as Pharmaceuticals

DAVIS, Zinna Northington 1625

Certificate of Mailing or Transmission I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage

for first class mail in an envelope addressed to the Mail Stop address below, or being facsimile transmitted to the USPTO, on the date indicated below.

Date of Deposit May 20, 2005

Printed Name of Person Signing Certificate. Bonnie Stein

Examiner:

Art Unit:

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT FOR WHICH THE FEE SPECIFIED UNDER 37 C.F.R. 1.97(c) IS REOUIRED

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Enclosed is an Information Disclosure Statement for which the fee specified in 37 C.F.R. 1.97(c) is required.

Please charge Deposit Account No. 18-1982 in the amount of \$180.00. Two duplicate copies of this sheet are enclosed. The Commissioner is authorized to charge any fees under 37 C.F.R.. 1.17(p) or credit any overpayment to Account No. 18-1982.

Respectfully submitted,

Barbara E. Kurys, Reg. No. 34,650

Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.

Patent Department

Route #202-206 / P.O. Box 6800

Bridgewater, NJ 08807-0800

Telephone (908) 231-2965

Telefax

(908) 231-2626

Aventis Docket No. DEAV2002/0050US NP

00000002 181982 DE /UL/ HOUST HINY RE